Wednesday, June 10, 2026

Patent intelligence · US

US 2021186075

COMPOSITIONS COMPRISING BACTERIAL STRAINS FOR USE IN INCREASING THE BIOAVAILABILITY OF AMINO ACIDS DERIVED FROM PROTEINS, AND RELATED FOOD P…

granted A61K 35/ 747 A IA61K/35745A61K/35747A61K/4506
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 25
Patent details — US 2021186075
Jurisdiction
US
Status
granted
Grant date
Jun 24, 2021
Expiration
Jun 19, 2041
Applicant
SOFAR SPA [IT]
CPC classes
A61K 35/ 747 A I, A61K/35745, A61K/35747, A61K/4506
View on Google Patents ↗

Quick answer

US 2021186075 (COMPOSITIONS COMPRISING BACTERIAL STRAINS FOR USE IN INCREASING THE BIOAVAILABILITY OF AMINO ACIDS DERIVED FROM PROTEINS, AND RELATED FOOD PRODUCT METHODS AND SYSTEMS) is held by SOFAR SPA [IT]. Status: granted. Granted Jun 24, 2021. Expires Jun 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
SOFAR SPA [IT]
Grant date
Expiration
Claims
CPC classes
A61K 35/ 747 A I, A61K/35745, A61K/35747, A61K/4506

More from SOFAR SPA [IT]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026027669

    BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB

    ALFASIGMA SPA [IT] · Expires Jan 31, 2046

    granted
  2. IT 202300014295

    COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO

    ALFASIGMA SPA [IT] · Expires Jan 7, 2045

    granted
  3. IT 202300012522

    FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.

    ALFASIGMA SPA [IT] · Expires Dec 17, 2044

    granted
  4. AU 2023257308

    USES OF FARNESOID X RECEPTOR AGONISTS

    ALFASIGMA S P A [IT] · Expires Oct 5, 2044

    granted
  5. IT 202300006237

    COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.

    ALFASIGMA SPA [IT] · Expires Oct 1, 2044

    granted
  6. IT 202300001434

    PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.

    ALFASIGMA SPA [IT] · Expires Jul 27, 2044

    granted
  7. CA 3263063

    VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)

    ALFASIGMA SPA [IT] · Expires Mar 23, 2044

    granted
  8. IT 202200013882

    PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.

    ALFASIGMA SPA [IT] · Expires Dec 30, 2043

    granted

Frequently asked questions

What is US patent 2021186075?

US 2021186075 (COMPOSITIONS COMPRISING BACTERIAL STRAINS FOR USE IN INCREASING THE BIOAVAILABILITY OF AMINO ACIDS DERIVED FROM PROTEINS, AND RELATED FOOD PRODUCT METHODS AND SYSTEMS) is held by SOFAR SPA [IT]. Status: granted. Granted Jun 24, 2021. Expires Jun 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 2021186075?

SOFAR SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does US 2021186075 expire?

Our index shows an expiration date of Jun 19, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.